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OBJECTIVE—The Type 1 Diabetes Genetics Consortium
(T1DGC) has assembled and genotyped a large collection of
multiplex families for the purpose of mapping genomic regions
linked to type 1 diabetes. In the current study, we tested for
evidence of loci associated with type 1 diabetes utilizing genome-
wide linkage scan data and family-based association methods.
RESEARCH DESIGN AND METHODS—A total of 2,496 mul-
tiplex families with type 1 diabetes were genotyped with a panel
of 6,090 single nucleotide polymorphisms (SNPs). Evidence of
association to disease was evaluated by the pedigree disequilib-
rium test. Signiﬁcant results were followed up by genotyping and
analyses in two independent sets of samples: 2,214 parent-
affected child trio families and a panel of 7,721 case and 9,679
control subjects.
RESULTS—Three of the SNPs most strongly associated with
type 1 diabetes localized to previously identiﬁed type 1 diabetes
risk loci: INS, IFIH1, and KIAA0350. A fourth strongly associ-
ated SNP, rs876498 (P  1.0  10
4), occurred in the sixth intron
of the UBASH3A locus at chromosome 21q22.3. Support for this
disease association was obtained in two additional independent
sample sets: families with type 1 diabetes (odds ratio [OR] 1.06
[95% CI 1.00–1.11]; P  0.023) and case and control subjects (1.14
[1.09–1.19]; P  7.5  10
8).
CONCLUSIONS—The T1DGC 6K SNP scan and follow-up stud-
ies reported here conﬁrm previously reported type 1 diabetes
associations at INS, IFIH1, and KIAA0350 and identify an
additional disease association on chromosome 21q22.3 in the
UBASH3A locus (OR 1.10 [95% CI 1.07–1.13]; P  4.4  10
12).
This gene and its ﬂanking regions are now validated targets for
further resequencing, genotyping, and functional studies in type
1 diabetes. Diabetes 57:2858–2861, 2008
G
enome-wide linkage and association studies
focused on candidate genes or interval map-
ping in type 1 diabetes have previously identi-
ﬁed a handful of risk loci that have been
conﬁrmed by multiple replications. Of these, the major
risk factor(s) reside within the HLA region on chromo-
some 6p21. Other, non-HLA type 1 diabetes loci have
comparatively small effects on disease risk relative to HLA
but comparable effect sizes to risk loci identiﬁed in other
common disorders. These include the insulin (INS) locus,
where variation is thought to impact the transcription and
expression of insulin, modulating thymic selection of
T-cells speciﬁc for this autoantigen (1,2). Variants at the
cytotoxic T-lymphocyte antigen (CTLA4) locus are impli-
cated in type 1 diabetes risk, potentially by altering the
production of differentially spliced products from the
locus that affects T-cell activation (3,4). Single nucleotide
polymorphisms (SNPs) in the interleukin-2 receptor 
(IL2RA) region, which encodes one chain of the het-
erodimeric interleukin-2 cytokine receptor, are associated
with type 1 diabetes (5). Finally, a nonsynonymous coding
region SNP in the protein tyrosine phosphatase, nonrecep-
tor type 22 (PTPN22) gene has been associated with type
1 diabetes as well as a number of other autoimmune
disorders (6–9). This SNP, which predicts an Arg to Trp
substitution at position 620, increases the activity of the
PTPN22 encoded phosphatase LYP, resulting in hypore-
sponsiveness of T-cells (10,11).
Recently, the approach of genome-wide association
scanning has been applied to type 1 diabetes (12–14). The
combination of high-density SNP coverage and large sam-
ple sizes for both initial screening and follow-up genotyp-
ing in these studies has both conﬁrmed known type 1
diabetes loci and identiﬁed a number of novel candidate
genes and regions. New associations with type 1 diabetes
have been identiﬁed and replicated for SNPs in two
regions on chromosome 12, 12q24 near C12orf30 and
12q13 near erythroblastic leukemia viral oncogene ho-
molog 3 (ERBB3); a region on 16p13 near C-type lectin
domain family 16, member A (CLEC16A/KIAA0350); a
region on 18p11 near protein tyrosine phosphatase, non-
receptor type 2 (PTPN2); and a region on 2q24 near
interferon induced with helicase C domain 1 (IFIH1)
(15,16). Detailed information about each of these type 1
diabetes–associated loci can be found at the T1DBase Web
site (www.t1dbase.org).
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BRIEF REPORT
2858 DIABETES, VOL. 57, OCTOBER 2008Most of the non-HLA type 1 diabetes risk loci are
characterized by ORs in the 1.15–1.3 range, and despite the
recent increase in the number of such loci identiﬁed and
conﬁrmed, it is unlikely that these known loci can account
for all of the genetic risk for type 1 diabetes (15). There-
fore, in the current study, we took advantage of a recently
completed genome-wide scan for linkage in multiplex
families with type 1 diabetes to explore whether alleles at
any of the 6,090 SNPs genotyped displayed evidence of
association with type 1 diabetes.
RESEARCH DESIGN AND METHODS
Families used for initial screening were selected from nine different sources:
the four Type 1 Diabetes Genetics Consortium (T1DGC) networks (Asia-
Paciﬁc [n  228], Europe [n  585], North America [n  370], and the U.K.
[n  124]), the Diabetes U.K. Warren Repository (n  429), the Human
Biological Data Interchange repository (n  424), the Joslin Diabetes Center
(n  112), the Steno Diabetes Center (n  146), and Sardinia (n  78). Details
on recruitment sites and the numbers of families contributed for each of the
T1DGC networks are accessible from the public side of the T1DGC Web site
(www.t1dgc.org). Minimum entry criteria for families included the presence
of at least one affected sibling pair, and availability of one or both biological
parents was preferred. Eligibility requirements for affected individuals in-
cluded documented type 1 diabetes with onset earlier than 35 years of age,
insulin use within 6 months of diagnosis, and the absence of any concomitant
disease or disorder associated with diabetes. In total, 2,496 families were
genotyped. Both parents were available for 72.9% of families; 18.8% had only
a single parent. Most families (91.7%) had exactly two affected full siblings;
4.1% had three and 0.3% had four or more affected siblings. The remaining
families had pairs that were either incomplete or were half siblings.
The family replication set of samples consisted of 2,214 parent-affected
child trio families derived from two sources. The Genetics of Kidneys in
Diabetes (GoKinD) study of diabetic nephropathy contributed 578 families.
Affected offspring in these families had type 1 diabetes diagnosed before 31
years of age, had initiated insulin therapy within 1 year of diagnosis, and had
continued insulin treatment uninterrupted since initiation. The remaining
1,636 families were selected from the Danish Society of Childhood Diabetes
and were all of Danish Caucasoid origin. Probands in these families were
diagnosed with type 1 diabetes before 15 years of age and had continued
insulin treatment since diagnosis. The case-control replication set consisted of
17,400 subjects, including 7,721 type 1 diabetic case subjects recruited as part
of the Juvenile Diabetes Research Foundation International/Wellcome Trust
British case collection and 9,679 control subjects from the British 1958 Birth
Cohort and the Wellcome Trust Case Control Blood Service (13,17).
Genotyping. Families included in the original genome-wide linkage scan
were all genotyped at the Center for Inherited Disease Research using the
Illumina Human Linkage-12 Genotyping Beadchip consisting of 6,090 SNPs.
Genotyping of SNP rs876498 in replication samples was performed using an
Eclipse genotyping assay (Nanogen). As quality control for accuracy of this
assay, a blinded resampling and genotyping of 366 families with type 1
diabetes from the initial genome-wide scan was performed.
Statistical analysis. Before statistical genetic analyses, genotype data were
evaluated for Mendelian errors using PedCheck (18). PREST (19) was used to
estimate the likelihood of each speciﬁed relationship in pedigrees given the
genotyping information. Based on these analyses, 43 families were removed
from further analysis due to the presence of a duplicate family, a duplicate
sample within the family, nonresolvable family errors, or missing genotype
information. Allelic association with type 1 diabetes within multiplex families
was assessed using the pedigree disequilibrium test (PDT) (20), which
provides a valid test of association in the presence of linkage in families with
multiple affected individuals. The PDT examines the discrepancy between the
alleles of heterozygote parents and those transmitted to affected offspring, as
well as the allelic difference between affected and unaffected siblings. Both
PDT-SUM and PDT-AVE tests (21) were carried out. Because these tests are
asymptotically equivalent, the PDT-AVE test, in which counts of trios and
pairs for each pedigree are weighted, is primarily reported here. PLINK
(v.1.02) (22) was used to assess allelic association to type 1 diabetes in trio
families, via the transmission/disequilibrium test (23), and in case-control
samples. A logistic regression model was used to estimate effect sizes, with
familial correlations being taken into account by the generalized estimating
equation method (24).
To combine results of the original genome scan and those of follow-up
studies, a weighted Z score–based ﬁxed effects meta-analysis method was
used. In brief, a Z statistic summarizing the magnitude of the P value for
association and direction of effect was generated for each study. An overall Z
statistic was then computed as a weighted average of the individual statistics,
and a corresponding P value for that statistic was computed. The weights
were proportional to the square root of the number of individuals in each
study and scaled such that the squared weights summed to 1. For the
meta-analysis of the effect size, the inverse variance was used as the weight
for each study.
RESULTS
After data cleaning, PDT was performed on the data from
5,943 markers genotyped in the family collection. Table 1
lists all SNPs with P  0.001 in this analysis. Only a single
marker, rs1004446, displayed evidence of association with
type 1 diabetes at a genome-wide signiﬁcance level (P 
2.5  10
9). This SNP is located in the INS-IGF2 region on
chromosome 11p15 and has previously been reported to
be associated with type 1 diabetes (14). Indeed, among the
16 SNPs listed in Table 1, 5 corresponded to previously
conﬁrmed type 1 diabetes loci identiﬁed through genome-
wide scanning: rs1004446 (INS-IGF2), a nonsynonymous
coding SNP rs1990760 (IFIH1), rs887864 (intron 18 of
CLEC16A/KIAA0350), and two SNPs, rs169679 and
rs1011094, that ﬂank the HLA region.
Given that the top three most associated SNPs (ranked
by statistical signiﬁcance in Table 1) correspond to con-
ﬁrmed type 1 diabetes risk loci, we examined the fourth-
ranked SNP, rs876498, for which there was also
substantial evidence of association with type 1 diabetes
(P  1.0  10
4 for PDT-AVE test and P  1.0  10
5 for
PDT-SUM test). Further impetus for follow-up study of
this SNP came from its location within the sixth intron of
the gene UBASH3A, which is expressed predominantly in
T-cells and is involved in the regulation of signaling from
the antigen receptor (25). The putative disease-associated
allele was relatively common, with a minor allele fre-
quency of 0.45 in unaffected founders. Blinded validation
genotyping was carried out in 366 of the original 2,496
T1DGC families by a second methodology to conﬁrm the
initial ﬁnding. A concordance rate of 100% was observed
between the original and the validation study. To conﬁrm
and extend the initial ﬁnding, rs876498 was genotyped in
additional independent populations, both family based
and case control (Table 2). Overall, there was highly
signiﬁcant evidence of association between the minor
TABLE 1
PDT results from 6K SNP scan at P  0.001
Chromosome SNP Position* P Locus†
11 rs1004446 2126719 2.5  10
9 INS
2 rs1990760 162949558 4.1  10
5 IFIH1
16 rs887864 11066386 7.1  10
5 KIAA0350
21 rs876498 42714896 1.0  10
4 UBASH3A
11 rs2076837 14931161 2.5  10
4
10 rs877783 72985946 3.6  10
4
2 rs6767 5021488 4.4  10
4
10 rs942434 7277013 5.8  10
4
6 rs169679 28964551 6.1  10
4 HLA
22 rs885978 17572780 6.4  10
4
2 rs1504 36977669 6.8  10
4
5 rs860732 179360006 7.0  10
4
6 rs1011094 28883961 7.9  10
4 HLA
7 rs1543851 64250422 8.4  10
4
8 rs1872283 107880067 9.0  10
4
3 rs353087 15165591 9.9  10
4
*Nucleotide position on indicated chromosome; †most proximal
locus to indicated SNP.
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12).
DISCUSSION
In the current study, we took advantage of available SNP
genotyping data from a linkage study of 2,496 multiplex
families with type 1 diabetes–affected sibling pairs. The
ability to use family-based testing for association allowed
the combined analysis of subjects selected from multiple
different geographic areas while reducing concerns re-
garding the potential effects of population stratiﬁcation.
Two approaches were used as an additional check for
potential heterogeneity from family collection in the nine
T1DGC regions. First, a meta-analysis combining the nine
individual PDT results provided a P  2.8  10
5, the same
magnitude of signiﬁcance as our combined data analysis.
Second, a Q statistic based on the association effect and
SE was computed. The association heterogeneity test (Q
5.15, 7 d.f. [one group has missing estimates]; P  0.64)
indicates no statistically signiﬁcant heterogeneity across
the regions of the T1DGC data. The validness of our test
for association can also be shown from the genomic
control number 1.02 obtained when the whole-genome
scan results were examined (26).
Although SNP coverage was extremely sparse for ge-
nome-wide association testing, an advantage was that the
SNP selection in the linkage panel of markers differs from
the higher density panels used in previous genome-wide
association studies. Three of the top four markers, ranked
by P value, corresponded to previously established type 1
diabetes risk loci. The fourth-ranked SNP mapped to
chromosome 21q22.3; no locus associated at genome-wide
signiﬁcance levels with type 1 diabetes or any other
autoimmune disorder has previously been mapped to this
chromosome. The region had, however, been previously
linked to type 1 diabetes in Scandinavian families (27), and
a region 10 Mb centromeric to rs876498 has been ﬁne-
mapped in Danish families (28). Furthermore, a type 1
diabetes risk locus on chromosome 21 might have been
anticipated given the increased frequency of Downs syn-
drome, caused by trisomy for chromosome 21, among type
1 diabetic patients (29). The ﬁndings reported here for
rs876498 were validated by a blinded 15% resample using
an alternative genotyping approach and then replicated in
independent sets of parent-affected child trio families and
case-control subjects. These studies provide compelling
evidence for association of the minor allele at this SNP,
rs876498, with type 1 diabetes.
The SNP rs876498 is located within the sixth intron of a
gene variously referred to as ubiquitin associated and SH3
domain containing, A (UBASH3A) (30), T-cell ubiquitin
ligand (TULA) (31), and suppressor of T-cell signaling 2
(Sts-2) (32). Based on the available data in HapMap
(release 23a), rs876498 is centrally located in a haplotype
block of 14 kb contained entirely within UBASH3A.
Flanking genes in the region are not obvious candidates,
on functional grounds, for involvement in type 1 diabetes
etiology, and they include the trefoil domain containing
family members TFF1 and TFF2; the transmembrane
serine protease TMPRSS3; RSPH1, which encodes a male
meiotic metaphase chromosome associated protein; and
the glycerol 3-phosphate transporter SLC37A1.
UBASH3A is expressed predominantly in T-cells, where
it interacts with c-CBL through its SH3 domain and binds
to ubiquitin and ubiquitylated proteins via its ubiquitin-
associated domain ((25). In T-cells, it acts in part by
inhibiting c-CBL–mediated downregulation of protein ty-
rosine kinases such as ZAP70 that are activated upon
T-cell receptor stimulation (32). In this regard, UBASH3A
is reminiscent of another identiﬁed type 1 diabetes risk
locus, PTPN22, whose product, LYP, also interacts with
c-CBL but directly downregulates some of the same pro-
tein tyrosine kinases by dephosphorylation (6,33).
UBASH3A has other functions in T-cells, including partic-
ipation in proapoptotic pathways (34). The functions of
UBASH3A make it an appealing candidate to contribute to
type 1 diabetes risk. While it may be premature to focus
exclusively on this single gene based upon the present
data, the signiﬁcant and replicated ﬁndings of association
reported here strongly suggest that a gene or genes in this
region contributes to risk for type 1 diabetes.
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